CMALX
Price
$26.81
Change
+$0.09 (+0.34%)
Updated
Dec 11 closing price
Net Assets
168.97M
RLBCX
Price
$39.94
Change
+$0.07 (+0.18%)
Updated
Dec 11 closing price
Net Assets
269.37B
Interact to see
Advertisement

CMALX vs RLBCX

Header iconCMALX vs RLBCX Comparison
Open Charts CMALX vs RLBCXBanner chart's image
Crawford Multi-Asset Income
Price$26.81
Change+$0.09 (+0.34%)
VolumeN/A
Net Assets168.97M
American Funds American Balanced R3
Price$39.94
Change+$0.07 (+0.18%)
VolumeN/A
Net Assets269.37B
CMALX vs RLBCX Comparison Chart in %
View a ticker or compare two or three
VS
CMALX vs. RLBCX commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMALX is a Hold and RLBCX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RLBCX has more cash in the bank: 269B vs. CMALX (169M). CMALX pays higher dividends than RLBCX: CMALX (4.10) vs RLBCX (1.44). CMALX was incepted earlier than RLBCX: CMALX (8 years) vs RLBCX (24 years). CMALX (1.24) is less costly to investors than RLBCX (0.89). RLBCX is a more actively managed with annual turnover of: 44.00 vs. CMALX (19.00). RLBCX has a lower initial minimum investment than CMALX: RLBCX (250) vs CMALX (10000). RLBCX annual gain was more profitable for investors over the last year : 10.24 vs. CMALX (3.10). CMALX return over 5 years is better than : 40.91 vs. RLBCX (38.90).
CMALXRLBCXCMALX / RLBCX
Total Expense Ratio0.990.89111%
Annual Report Gross Expense Ratio1.240.89139%
Fund Existence8 years24 years-
Gain YTD5.00217.87628%
Front LoadN/AN/A-
Min. Initial Investment100002504,000%
Min. Initial Investment IRAN/AN/A-
Net Assets169M269B0%
Annual Yield % from dividends4.101.44285%
Returns for 1 year3.1010.2430%
Returns for 3 years21.8142.5751%
Returns for 5 years40.9138.90105%
Returns for 10 yearsN/A77.32-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOPX42.940.37
+0.87%
Patient Opportunity C
JRSNX12.150.04
+0.33%
JH Adaptive Risk Mgd U.S. Eq N
JMCGX32.390.09
+0.28%
Jacob Discovery Fd Inv
DCFGX35.33-0.02
-0.06%
Dunham Focused Large Cap Growth C
BGSCX52.90-0.39
-0.73%
BlackRock Technology Opportunities Inv C